Molecule to Medicine Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 49

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 1

Molecule to Medicine General Information

Description

Provider of biotechnology and pharmaceutical consulting services intended to design and manage drug discovery. The company's services offer operational and project assistance from the formation stage and guide the evolution of companies on the right trajectory with the translation of drug discovery activities, enabling small biotech companies to achieve the efficient discovery, development, and global commercialization of new human therapeutics.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 99 Park Drive
  • Abingdon OX14 4RY
  • England, United Kingdom
+44 01235
Primary Industry
Consulting Services (B2B)
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 99 Park Drive
  • Abingdon OX14 4RY
  • England, United Kingdom
+44 01235

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Molecule to Medicine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC 01-May-2026 Completed Generating Revenue
To view Molecule to Medicine’s complete valuation and funding history, request access »

Molecule to Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Molecule to Medicine Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
UniQuest Extension Fund Venture Capital Minority
To view Molecule to Medicine’s complete investors history, request access »

Molecule to Medicine Investments (2)

Molecule to Medicine’s most recent deal was a Joint Venture with Lucia Bio. The deal was made on 01-Jan-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Lucia Bio 01-Jan-2024 Joint Venture Drug Discovery
ThirtyFiveBio 26-Jan-2021 Joint Venture Drug Discovery
To view Molecule to Medicine’s complete investments history, request access »

Molecule to Medicine FAQs

  • When was Molecule to Medicine founded?

    Molecule to Medicine was founded in 2015.

  • Where is Molecule to Medicine headquartered?

    Molecule to Medicine is headquartered in Abingdon, United Kingdom.

  • What is the size of Molecule to Medicine?

    Molecule to Medicine has 49 total employees.

  • What industry is Molecule to Medicine in?

    Molecule to Medicine’s primary industry is Consulting Services (B2B).

  • Is Molecule to Medicine a private or public company?

    Molecule to Medicine is a Private company.

  • What is Molecule to Medicine’s current revenue?

    The current revenue for Molecule to Medicine is .

  • Who are Molecule to Medicine’s investors?

    UniQuest Extension Fund has invested in Molecule to Medicine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process